GTBP

GT Biopharma, Inc. [GTBP] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

GTBP Stock Summary

Top 10 Correlated ETFs

GTBP


Top 10 Correlated Stocks

GTBP


In the News

11:09 29 Mar 2024 GTBP

Here's Why GT Biopharma, Inc. (GTBP) Is a Great 'Buy the Bottom' Stock Now

GT Biopharma, Inc. (GTBP) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

01:46 29 Mar 2024 GTBP

All You Need to Know About GT Biopharma, Inc. (GTBP) Rating Upgrade to Buy

GT Biopharma, Inc. (GTBP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

09:00 29 Mar 2024 GTBP

GT Biopharma to Participate in the H.C. Wainwright Cell Therapy Virtual Conference

BRISBANE, CALIFORNIA, Feb. 24, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® platform, today announced that Dr. Jeffrey Miller, MD, GT Bipharma's Consulting Chief Medical Officer and Chief Scientific Officer, will present a corporate overview at H.C. Wainwright's Cell Therapy Virtual Conference taking place on February 28, 2023. Company management will also be participating in 1x1 meetings during the event.

07:30 29 Mar 2024 GTBP

GT Biopharma to Participate in the H.C. Wainwright 24th Annual Global Investment Conference in September

BRISBANE, Calif., Sept. 08, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® platform, today announced that management will present in-person at H.C. Wainwright's 24th Annual Global Investment Conference taking place September 12-14, 2022 at the Lotte New York Palace. Company management will also be participating in 1x1 meetings during the event.

08:00 29 Mar 2024 GTBP

GT Biopharma to Participate at H.C. Wainwright Hybrid Global Investment Conference

BRISBANE, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP), an immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary tri-specific natural killer (NK) cell engager, TriKE® protein biologic technology platform, announced that management will present at H.C. Wainwright's Hybrid Global Investment Conference. The conference will take place May 23-26, 2022 at the Fontainebleau, Miami Beach Hotel, Miami Beach, Florida.

07:30 29 Mar 2024 GTBP

GT Biopharma to Present Pre-Clinical Data at Upcoming Medical Conferences

BRISBANE, Calif., Feb. 24, 2022 /PRNewswire/ -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® protein biologic technology platform, announced today that GT Biopharma will be participating in the following upcoming medical conferences: Abstract and poster presentation details are as follows: ESMO Targeted Anticancer Therapies Congress (TAT) (March 7-8, 2022) Title: Driving NK cell immunotherapy against NSCLC, in the context of hypoxia, using Tri-specific Killer Engager (TriKE)  Abstract Number:   250 Session:    Immunotherapy Presentation Type:  Poster Session Date and Time:  March 7, 9:20AM (CET) (On-demand e-poster display)   Location:          Virtual Poster Board Number:   17P 48th Annual European Society for Blood and Marrow Transplantation (EBMT) (March 19-23, 2022) Title:                  A Tri-specific Killer Engager (TriKE) against B7-H3 enhances NK cell mediated killing of multiple myeloma Abstract Number:        AS-EBMT-2022-00508 Session:                       New Drugs- and Cell-Based Immune Therapies Presentation Type:      Poster Session Date and Time:  March 19, 2022, 9:50 AM (CET) Location:                        Prague Congress Center, Czech Republic Poster Board Number:  P153 American Association for Cancer Research (AACR) Annual Meeting (April 8-13, 2022) Title: GTB-5550 (cam16-IL15-camB7H3) Tri-specific Killer Engager (TriKE®) drives natural killer cell activation and antibody dependent cellular cytotoxicity against head and neck squamous cell carcinomas Abstract Number: Abstract control number 3334, permanent abstract number 3435 Session: Clinical Research Excluding Trials, Combination Immunotherapies / Therapeutic Antibodies Presentation Type: Poster Session Date and Time: April 12, 2022 1:30 PM – 5:00 PM Location: Ernest N.

07:30 29 Mar 2024 GTBP

GT Biopharma to Present at B. Riley Securities' Virtual Oncology Conference

BRISBANE, Calif., Jan. 20, 2022 /PRNewswire/ -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE ® protein biologic technology platform, announced today that Dr. Greg Berk, President of R&D, Chief Medical Officer and Interim CEO will be participating in a Fireside Chat at the upcoming B.

01:44 29 Mar 2024 GTBP

GT Biopharma: Shift In Therapy Strategy Reduces Attractiveness

GT Biopharma: Shift In Therapy Strategy Reduces Attractiveness

07:00 29 Mar 2024 GTBP

GT BioPharma's Next Generation Camelid TriKE® Nanobody Platform Highlighted at ESMO Congress 2021

BEVERLY HILLS, Calif., Sept. 20, 2021 /PRNewswire/ -- GT Biopharma, Inc. (the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE platform, today announced Dr. Jeffrey Miller's mini-oral presentation at the European Society for Medical Oncology (ESMO) Congress 2021.

01:44 29 Mar 2024 GTBP

OXIS International Inc. (GTBP) Moves to Buy: Rationale Behind the Upgrade

OXIS International Inc. (GTBP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

GTBP Financial details

Company Rating
Sell
Market Cap
6.34M
Income
-13.77M
Revenue
0
Book val./share
0.24
Cash/share
0.39
Dividend
-
Dividend %
-
Employees
2
Optionable
No
Shortable
Yes
Earnings
13 May 2024
P/E
-0.71
Forward P/E
-0.23
PEG
0.09
P/S
-
P/B
0.98
P/C
11.36
P/FCF
-0.89
Quick Ratio
3.15
Current Ratio
3.15
Debt / Equity
0.01
LT Debt / Equity
-
-
-
EPS (TTM)
-0.38
EPS next Y
-19.2
EPS next Q
-2.7
EPS this Y
-69.23%
EPS next Y
4972.66%
EPS next 5Y
6003.04%
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
18.75%
-
-
-
-
SMA20
4.33%
SMA50
-37.19%
SMA100
-43.12%
Inst Own
7.9%
Inst Trans
0.94%
ROA
-85%
ROE
-118%
ROC
-1.46%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
1.38M
Shs Float
1.24M
-
-
-
-
Target Price
-
52W Range
3.52-19.14
52W High
-76.68%
52W Low
+47.67%
RSI
48.05
Rel Volume
1.01
Avg Volume
10.71K
Volume
10.83K
Perf Week
-0.89%
Perf Month
17.82%
Perf Quarter
-37.87%
Perf Half Y
-42.09%
-
-
-
-
Beta
0.576
-
-
Volatility
0.23%, 0.27%
Prev Close
1.37%
Price
4.43
Change
0.68%

GTBP Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2018-12-312019-12-312020-12-312021-12-31 2022-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000
Net income per share
-87.7-12.04-7.21-2.08-0.64
Operating cash flow per share
-3.61-1.08-1.66-0.55-0.48
Free cash flow per share
-3.62-1.08-1.66-0.55-0.48
Cash per share
0.020.011.211.140.52
Book value per share
3.9-5.65-6.670.780.37
Tangible book value per share
-4.7-5.7-6.710.780.37
Share holders equity per share
3.9-5.65-6.670.780.37
Interest debt per share
6.744.576.760.030.01
Market cap
979.69M139.85M948.26M2.58B846.73M
Enterprise value
990.43M153.18M969.3M2.57B841.24M
P/E ratio
-3.78-3.43-29.99-43.89-41.3
Price to sales ratio
00000
POCF ratio
-91.76-38.22-130.58-165.08-55.64
PFCF ratio
-91.45-38.22-130.58-165.08-55.64
P/B Ratio
84.9-7.31-32.4117.5872.16
PTB ratio
84.9-7.31-32.4117.5872.16
EV to sales
00000
Enterprise value over EBITDA
-45.97-13.37-50.06-44.67-40.13
EV to operating cash flow
-92.76-41.86-133.48-164.51-55.28
EV to free cash flow
-92.45-41.86-133.48-164.51-55.28
Earnings yield
-0.26-0.29-0.03-0.02-0.02
Free cash flow yield
-0.01-0.03-0.01-0.01-0.02
Debt to equity
0.94-0.7-0.900.01
Debt to assets
0.4333.734.6500.01
Net debt to EBITDA
-0.5-1.16-1.090.160.26
Current ratio
0.010.010.163.143.35
Interest coverage
-27.43-7.55-2.04-80.1-2.66K
Income quality
0.040.090.260.270.73
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
0.990000
Capex to operating cash flow
00000
Capex to revenue
00000
Capex to depreciation
-5.140000
Stock based compensation to revenue
00000
Graham number
87.7839.1432.96.042.31
ROIC
-1.322.992.58-2.65-1.73
Return on tangible assets
-1.89K-102.97-5.58-1.82-1.23
Graham Net
-4.73-5.81-6.790.770.36
Working capital
-13.94M-19.43M-29.43M21.91M11.62M
Tangible asset value
-13.89M-19.31M-29.43M21.91M11.73M
Net current asset value
-13.94M-19.43M-29.43M21.91M11.56M
Invested capital
0.94-0.7-0.900.01
Average receivables
00000
Average payables
2.15M1.85M2.09M5.22M5.66M
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
0177.03K000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
-22.462.131.08-2.68-1.75
Capex per share
-0.010000

Quarterly Fundamentals Overview

Last date of statement is 2023-09-30 for Q3

Metric History 2022-09-302022-12-312023-03-312023-06-30 2023-09-30
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000
Net income per share
-0.21-0.17-0.1-0.05-0.06
Operating cash flow per share
-0.09-0.13-0.07-0.05-0.05
Free cash flow per share
-0.09-0.13-0.07-0.05-0.05
Cash per share
0.660.520.510.450.39
Book value per share
0.510.370.330.290.24
Tangible book value per share
0.510.370.330.290.24
Share holders equity per share
0.510.370.330.290.24
Interest debt per share
0.010.010.0100
Market cap
1.66B846.73M644.91M376.02M296.55M
Enterprise value
1.65B841.24M643.01M373.37M293.99M
P/E ratio
-62.46-38.83-41.27-47.19-30.69
Price to sales ratio
00000
POCF ratio
-567.82-197.01-221.92-194.32-150.99
PFCF ratio
-567.82-197.01-221.92-194.32-150.99
P/B Ratio
103.8572.1649.4131.9729.64
PTB ratio
103.8572.1649.4131.9729.64
EV to sales
00000
Enterprise value over EBITDA
-239.25-149.23-183.67-109.78-94.17
EV to operating cash flow
-567.04-195.73-221.27-192.96-149.69
EV to free cash flow
-567.04-195.73-221.27-192.96-149.69
Earnings yield
0-0.01-0.01-0.01-0.01
Free cash flow yield
0-0.010-0.01-0.01
Debt to equity
0.010.010.010.010.01
Debt to assets
0.010.010.010.010.01
Net debt to EBITDA
0.330.980.540.780.82
Current ratio
4.153.354.893.723.15
Interest coverage
-65.64-722.25-17.29-3.62K0
Income quality
0.420.7712.80.970.81
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
00000
Capex to revenue
00000
Capex to depreciation
00000
Stock based compensation to revenue
00000
Graham number
1.551.190.870.570.57
ROIC
-0.41-0.47-4.73-0.27-0.31
Return on tangible assets
-0.31-0.33-0.19-0.11-0.15
Graham Net
0.50.360.330.290.24
Working capital
15.85M11.62M15.86M13.18M10.96M
Tangible asset value
15.95M11.73M13.05M11.76M10.01M
Net current asset value
15.76M11.56M12.9M11.64M9.91M
Invested capital
0.010.010.010.010.01
Average receivables
00000
Average payables
5.29M3.23M3.14M3.32M3.74M
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
-0.42-0.46-0.3-0.17-0.24
Capex per share
00000

GTBP Frequently Asked Questions

What is GT Biopharma, Inc. stock symbol ?

GT Biopharma, Inc. is a US stock , located in Brisbane of Ca and trading under the symbol GTBP

What is GT Biopharma, Inc. stock quote today ?

GT Biopharma, Inc. stock price is $4.43 today.

Is GT Biopharma, Inc. stock public?

Yes, GT Biopharma, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap